How much XOS should you take per day?

Published clinical studies report effects for xylo-oligosaccharides at approximately 1.4 to 2.8 grams per day. This is substantially lower than fructo-oligosaccharides (FOS), which typically require 8 to 10 grams per day, or inulin at 5 to 8 grams per day.

Is XOS cheaper than FOS or inulin?

Per kilogram XOS costs more. Per effective dose it is usually cheaper, because it works at roughly a fifth of the dose. At Indian market prices, an effective daily dose of XOS costs around one to one and a half rupees, against roughly three rupees for FOS and over five rupees for inulin or GOS.

Is XOS approved for food use internationally?

XOS is GRAS in the United States, approved as a Novel Food in the European Union under Regulation (EU) 2015/2283, recognised as FOSHU in Japan permitting health claims, approved as a new food resource in China, and has received a non-novel determination in Canada for XOS derived from corncob and sugarcane.

Why does XOS work at a lower dose than other prebiotics?

XOS is highly selective for beneficial Bifidobacterium and resists digestion in the upper gastrointestinal tract, with reported degradation by human digestive enzymes below 0.4 percent. Prebiotics such as FOS and IMO can degrade by over 10 percent before reaching the colon, so a higher starting dose is required to deliver the same amount to the site of action.

XOS Prebiotics — Cost-in-Use, Dosage & Regulatory Status

Cost per effective dose

Per kilo is the wrong number.

A prebiotic that needs 10 g to work is not cheap at ₹300/kg. What matters is what one effective dose costs — and on that basis the ranking inverts completely.

Cost per effective dose of common prebiotics at Indian market prices
Prebiotic	Studied dose	Indian bulk price	Cost per dose
XOS (95%)	1.4–2.8 g	₹700–950/kg	₹0.98–1.33
FOS (95%)	8–10 g	₹300/kg	₹3.00
Inulin (90%)	5–8 g	₹650/kg	₹5.20
GOS (95%)	3–5 g	₹1,100/kg	₹5.50

Prices are third-party Indian bulk market reference points, not BioVikas quotations. Dose ranges are from published clinical literature — see references below.

<0.4%

Survives digestion

XOS degradation by human digestive enzymes is reported below 0.4%. FOS and IMO can exceed 10%, so more must be dosed to deliver the same amount to the colon.

pH 2.5–8

Survives processing

Stable across acidic beverages and through high-heat processes including extrusion, where bulkier fibres degrade.

1–2%

No texture penalty

Typical inclusion is low enough to avoid the mouthfeel, viscosity and moisture-binding problems that high-dose fibres introduce.

Free tool

Cost-in-use calculator.

Enter what you use today. The tool returns what one effective dose actually costs you, and what an equivalent XOS price would be at exact parity — using your numbers, not ours.

Your cost per dose ₹2.70

Using FOS at your stated price

XOS parity price ₹964/kg

What XOS could cost with zero extra spend

XOS dose needed 2.8 g

Conservative end of the studied range

Price you could pay, at equal cost per dose

FOS today

₹300/kg

XOS at parity

₹964/kg

XOS could cost up to 3.2× more per kilogram and still cost you the same per dose.

Method

cost per dose = (price per kg ÷ 1000) × dose in grams
XOS parity price = (cost per dose ÷ 2.8 g) × 1000

Parity uses 2.8 g — the upper, more conservative end of the studied XOS range. At the lower end of 1.4 g the parity price would be roughly double what is shown.

The underdosing problem

Most products state less than trials used.

A low dose per serving is what makes a cheap per-kilo prebiotic look affordable. It is also why many finished products carry a fibre that never reaches the dose the research was built on — which is the whole reason cost-in-use, not price per kilo, is the number that matters.

Our dose checker lets you test any product against the published ranges — including ours. It names no brands.

Check a product label →

Regulatory status

Already cleared in the markets that matter.

XOS is not a novel or speculative ingredient. It carries clearance in every major export market — which removes the regulatory risk usually attached to a new bio-based input.

Market	Status	What it permits
United States	GRAS	Use in food without pre-market approval
European Union	Novel Food approved	Authorised under Reg (EU) 2015/2283 for bakery, dairy, jelly, chocolate and soy drinks
Japan	FOSHU	Food for Specified Health Uses — health claims permitted subject to approval
China	New food resource	Approved for food use
Canada	Non-novel determination	Specifically covers XOS derived from corncob and sugarcane — our feedstocks
India	FSSAI pathway	Food use subject to standard FSSAI approval; feed use carries no equivalent barrier

Status of the XOS ingredient class, not of any BioVikas product. Our own clearances follow the commercial roadmap below. Confirm current requirements with the relevant authority before relying on this for a filing.

Where this goes

Feed first. Synbiotics eventually.

Each step up needs testing and clearance the step below does not. We start where the bar is lowest and the need is most urgent, and earn the right to climb.

01

Animal & aqua feed

Beachhead

No human-food clearance required, so qualification runs in weeks. Demand is being pushed hard by the move away from antibiotic growth promoters — most acutely in shrimp, where residue findings are actively costing exporters rejected consignments.

02

Food & beverage

Functional foods, drinks and supplements. Requires FSSAI clearance domestically, and the low dose is a formulation advantage rather than merely a cost one — it fits formats bulkier fibres cannot enter.

03

Nutraceutical & clinical

Planned

Higher purity, tighter chain-length control, and the documentation and liability that clinical-grade consistency demands. The molecule does not change so much as the assurance around it does.

04

Bespoke synbiotics

The goal

The end point is not selling XOS by the tonne. It is co-developing finished synbiotic products with a pharmaceutical or nutrition partner — matching specific chain-length profiles to specific probiotic strains. That is a formulation business, not an ingredient business, and it is where the value concentrates.

References & data sources

EFSA Panel on Nutrition, Novel Foods and Food Allergens. Safety of xylo-oligosaccharides (XOS) as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal. — basis for EU Novel Food status and safety assessment.
Global Prebiotic Association. Prebiotic Type Spotlight: Xylooligosaccharides (XOS) — dosage, selectivity and comparative efficacy.
Frontiers in Nutrition. The preparation technology and application of xylo-oligosaccharide as prebiotics in different fields: a review — production routes, stability and application data.
Comparative effective-dose ranges for XOS, FOS, GOS and inulin are drawn from published double-blind, randomised, placebo-controlled trial literature. Individual response varies; these are population-level study doses, not recommendations.
Indian bulk price reference points are third-party B2B list prices observed in the domestic market and are indicative only. They are not BioVikas quotations and will move with grade, volume and contract terms.
Regulatory status compiled from published determinations by the US FDA (GRAS), EFSA (Novel Food, Reg (EU) 2015/2283), Japan FOSHU, China new food resource approval, and Health Canada non-novel determination for corncob- and sugarcane-derived XOS.

Nothing on this page is medical, nutritional or regulatory advice. Figures are provided for technical orientation and should be verified against primary sources before use in a filing, formulation or investment decision.

I formulate with prebiotics

Feed, food, beverage or supplement formulators evaluating a lower-dose, heat- and acid-stable option.

Request specifications

I want to co-develop

Pharma and nutrition partners interested in bespoke synbiotic formulations rather than bulk ingredient supply.

Start a conversation

XOS is already the cheapest prebiotic per effective dose.